Back to search
Respiratory Syncytial Virus Vaccination
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Respiratory Syncytial Virus Vaccination trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Respiratory Syncytial Virus Vaccination trials you may qualify forThis study aims to check how safe and well-tolerated a second dose of RSVpreF is when given during later pregnancies, and to see how long the immunity lasts fro…
This is a prospective, randomized, open-label clinical trial to evaluate the safety of administration of respiratory syncytial virus (RSV) preventive monoclonal…
This clinical trial is being done to learn more about how well a vaccine (Arexvy®) for respiratory syncytial virus, also known as RSV, works in people with weak…
Respiratory syncytial virus (RSV) is a common cause of respiratory tract infections leading to hospitalizations in infants and in elderly. Arexvy is an approved…
This phase 1 study will evaluate the safety, reactogenicity, and immunogenicity of 3 different dose levels of SCB-1022 and SCB-1033 in healthy adults aged 60-85…
Bronchiolitis is a viral lower respiratory tract infection, caused in 50 to 80% of cases by the respiratory syncytial virus (RSV). Although generally mild, RSV…
This study will use a retrospective cohort design and will be conducted within routinely collected national healthcare and statutory demographic datasets held b…
Respiratory Syncytial Virus (RSV) is the leading cause of lower respiratory tract infections (LRTIs) in infants and young children. It is also a leading cause o…